ELiBio is a software solution dedicated to characterize liver health in patients suffering from metabolic liver diseases such as MAFLD (Metabolic-Associated Fatty Liver Disease) and MASH (Metabolic Dysfunction-Associated Steatohepatitis). It allows clinicians to visualize, measure, and monitor liver tissue composition (3D fat & iron content and 3D fibrosis presence and severity) from a single hold breathing MRI scan lasting less than 20 seconds.
Access to clear and easily interpretable visual reports allows your clinicians to:
ELiBio® technology can be used in clinical trials to assess the impact of a drug candidate or an approved treatment on the liver.
In addition to standard quantitative measurements and maps of the liver, ELiBio® also produces abdominal fat analysis, with visualization of fat composition (polyunsaturated, monounsaturated, saturated), visceral fat distribution and intra-abdominal to subcutaneous fat ratio.
Designed for University Hospitals, Centers specialized in liver diseases, Pharmaceutical companies and CROs
